SalivaDirect: A simplified and flexible platform to enhance SARS-CoV-2 testing capacity.

Background: Scaling SARS-CoV-2 testing to meet demands of safe reopenings continues to be plagued by assay costs and supply chain shortages. In response, we developed SalivaDirect, which received Emergency Use Authorization (EUA) from the U.S.